274 related articles for article (PubMed ID: 29847610)
1. Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
Donigan JM; Hyde MA; Goldgar DE; Hadley ML; Bowling M; Bowen GM
JAMA Dermatol; 2018 Aug; 154(8):885-889. PubMed ID: 29847610
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
[TBL] [Abstract][Full Text] [Related]
3. Interventions for melanoma in situ, including lentigo maligna.
Tzellos T; Kyrgidis A; Mocellin S; Chan AW; Pilati P; Apalla Z
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010308. PubMed ID: 25526608
[TBL] [Abstract][Full Text] [Related]
4. Strategies for Reducing Final Surgical Defect Sizes in the Treatment of Lentigo Maligna.
Sampson BP; Bowen GM
Dermatol Surg; 2020 Apr; 46(4):537-545. PubMed ID: 31464705
[TBL] [Abstract][Full Text] [Related]
5. Treatment of lentigo maligna with imiquimod before staged excision.
Cotter MA; McKenna JK; Bowen GM
Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
[TBL] [Abstract][Full Text] [Related]
6. Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
Chambers M; Swetter SM; Baker C; Saunders E; Chapman MS
J Drugs Dermatol; 2021 Mar; 20(3):346-348. PubMed ID: 33683087
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment.
Tio DCKS; van Montfrans C; Ruijter CGH; Hoekzema R; Bekkenk MW
Acta Derm Venereol; 2019 Sep; 99(10):884-888. PubMed ID: 31233181
[TBL] [Abstract][Full Text] [Related]
8. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
Gautschi M; Oberholzer PA; Baumgartner M; Gadaldi K; Yawalkar N; Hunger RE
J Am Acad Dermatol; 2016 Jan; 74(1):81-87.e1. PubMed ID: 26601565
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
10. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up.
Bub JL; Berg D; Slee A; Odland PB
Arch Dermatol; 2004 May; 140(5):552-8. PubMed ID: 15148099
[TBL] [Abstract][Full Text] [Related]
11. Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma.
Matas-Nadal C; Sòria X; García-de-la-Fuente MR; Huerva V; Ortega E; Vilardell F; Gatius S; Casanova JM; Martí RM
J Dermatol; 2018 May; 45(5):564-570. PubMed ID: 29430695
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of imiquimod-treated lentigo maligna.
Papanikolaou M; Lawrence CM
Clin Exp Dermatol; 2019 Aug; 44(6):631-636. PubMed ID: 30663131
[TBL] [Abstract][Full Text] [Related]
13. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.
Erickson C; Miller SJ
Int J Dermatol; 2010 May; 49(5):482-91. PubMed ID: 20534080
[TBL] [Abstract][Full Text] [Related]
14. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment.
McKenna JK; Florell SR; Goldman GD; Bowen GM
Dermatol Surg; 2006 Apr; 32(4):493-504. PubMed ID: 16681656
[TBL] [Abstract][Full Text] [Related]
15. Geometric staged excision for the treatment of lentigo maligna and lentigo maligna melanoma: a long-term experience with literature review.
Abdelmalek M; Loosemore MP; Hurt MA; Hruza G
Arch Dermatol; 2012 May; 148(5):599-604. PubMed ID: 22782151
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lentigo maligna with imiquimod 5% cream.
Hopson B; Richey D; Sajben FP
J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
[TBL] [Abstract][Full Text] [Related]
17. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients.
Van Meurs T; Van Doorn R; Kirtschig G
Dermatol Surg; 2010 Jun; 36(6):853-8. PubMed ID: 20618370
[TBL] [Abstract][Full Text] [Related]
18. Improving management and patient care in lentigo maligna by mapping with in vivo confocal microscopy.
Guitera P; Moloney FJ; Menzies SW; Stretch JR; Quinn MJ; Hong A; Fogarty G; Scolyer RA
JAMA Dermatol; 2013 Jun; 149(6):692-8. PubMed ID: 23553208
[TBL] [Abstract][Full Text] [Related]
19. Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM; Russell-Jones R; Barlow RJ
Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
[TBL] [Abstract][Full Text] [Related]
20. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.
Kirtschig G; van Meurs T; van Doorn R
Acta Derm Venereol; 2015 Jan; 95(1):83-5. PubMed ID: 24696093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
